| Primary |
| Convulsion |
49.5% |
| Epilepsy |
10.5% |
| Ill-defined Disorder |
10.5% |
| Grand Mal Convulsion |
4.1% |
| Drug Use For Unknown Indication |
3.2% |
| Pain |
2.7% |
| Hypertension |
2.3% |
| Blood Cholesterol Increased |
1.8% |
| Diabetes Mellitus |
1.8% |
| Rash |
1.8% |
| Agitation |
1.4% |
| Cardiac Disorder |
1.4% |
| Constipation |
1.4% |
| Convulsion Prophylaxis |
1.4% |
| Fluid Retention |
1.4% |
| Pneumococcal Immunisation |
1.4% |
| Blood Pressure Abnormal |
0.9% |
| Depression |
0.9% |
| Hyperlipidaemia |
0.9% |
| Mineral Supplementation |
0.9% |
|
| Stevens-johnson Syndrome |
30.9% |
| Pharmaceutical Product Complaint |
13.8% |
| Vomiting |
8.5% |
| Convulsion |
5.3% |
| Treatment Noncompliance |
5.3% |
| Splenomegaly |
4.3% |
| Grand Mal Convulsion |
3.2% |
| Vertigo |
3.2% |
| Chest Pain |
2.1% |
| Drug Hypersensitivity |
2.1% |
| Drug Ineffective |
2.1% |
| Loss Of Consciousness |
2.1% |
| Memory Impairment |
2.1% |
| Rash Maculo-papular |
2.1% |
| Renal Failure |
2.1% |
| Rhabdomyolysis |
2.1% |
| Sleep Disorder |
2.1% |
| Somnolence |
2.1% |
| Thoracic Vertebral Fracture |
2.1% |
| Urinary Tract Infection |
2.1% |
|
| Secondary |
| Convulsion |
51.7% |
| Epilepsy |
6.8% |
| Pain |
6.0% |
| Drug Use For Unknown Indication |
5.6% |
| Grand Mal Convulsion |
5.6% |
| Ill-defined Disorder |
4.7% |
| Depression |
2.1% |
| Sleep Disorder |
2.1% |
| Anxiety |
1.7% |
| Constipation |
1.7% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Multiple Sclerosis |
1.7% |
| Pneumonia |
1.7% |
| Type 2 Diabetes Mellitus |
1.7% |
| Clostridial Infection |
0.9% |
| Convulsion Prophylaxis |
0.9% |
| Fibromyalgia |
0.9% |
| Mixed Oligo-astrocytoma |
0.9% |
| Multiple Allergies |
0.9% |
| Pyrexia |
0.9% |
|
| Stevens-johnson Syndrome |
60.7% |
| Toxic Epidermal Necrolysis |
6.0% |
| Weight Decreased |
4.8% |
| Pain In Extremity |
3.6% |
| Back Pain |
2.4% |
| Intervertebral Disc Compression |
2.4% |
| Peripheral Coldness |
2.4% |
| Seasonal Allergy |
2.4% |
| Weight Fluctuation |
2.4% |
| Ataxia |
1.2% |
| Benign Prostatic Hyperplasia |
1.2% |
| Drug Hypersensitivity |
1.2% |
| Drug Toxicity |
1.2% |
| Essential Hypertension |
1.2% |
| Hypothyroidism |
1.2% |
| Nasopharyngitis |
1.2% |
| Neuropathy Peripheral |
1.2% |
| Subdural Haematoma |
1.2% |
| Suicidal Ideation |
1.2% |
| Visual Acuity Reduced |
1.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
16.7% |
| Bone Marrow Conditioning Regimen |
10.7% |
| Convulsion |
7.1% |
| Glioblastoma Multiforme |
7.1% |
| Constipation |
4.8% |
| Depression |
4.8% |
| Hypersensitivity |
4.8% |
| Hypertension |
4.8% |
| Myelodysplastic Syndrome |
4.8% |
| Renal Failure Chronic |
4.8% |
| Epilepsy |
3.6% |
| Gastrooesophageal Reflux Disease |
3.6% |
| Hiv Infection |
3.6% |
| Lung Neoplasm Malignant |
3.6% |
| Multiple Sclerosis |
3.6% |
| Brain Neoplasm |
2.4% |
| Gastrointestinal Disorder |
2.4% |
| Multiple Myeloma |
2.4% |
| Osteopenia |
2.4% |
| Osteoporosis |
2.4% |
|
| Vomiting |
15.2% |
| Pyrexia |
12.1% |
| White Blood Cell Count Decreased |
9.1% |
| Drug Toxicity |
6.1% |
| Tremor |
6.1% |
| Weight Decreased |
6.1% |
| White Blood Cell Count Increased |
6.1% |
| Convulsion |
3.0% |
| Death |
3.0% |
| Drug Interaction |
3.0% |
| Dysarthria |
3.0% |
| Dyspnoea |
3.0% |
| Electrocardiogram Qt Prolonged |
3.0% |
| Fall |
3.0% |
| Hepatic Enzyme Increased |
3.0% |
| Hypersensitivity |
3.0% |
| Intentional Overdose |
3.0% |
| Lethargy |
3.0% |
| Leukopenia |
3.0% |
| Malignant Neoplasm Progression |
3.0% |
|
| Interacting |
| Convulsion |
50.0% |
| Smoking Cessation Therapy |
50.0% |
|
|
